Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
March 9 midday announcement overview: Xiangjia Co., Ltd. sold 2.9368 million live poultry units by February 2026
Xiangjia Co., Ltd. announced that in February 2026, the company sold 2.9368 million live poultry, with sales revenue of 67.3483 million yuan. The average selling price was 10.5 yuan/kg. Month-over-month changes were -27.17%, -25.46%, and 3.37%, respectively, while year-over-year changes were -23.52%, -5.83%, and 20.43%. The total live poultry sales for February 2026 were 2.9368 million units, with sales revenue of 67.3483 million yuan. In February 2025, live poultry sales were 3.84 million units, with sales revenue of 71.515 million yuan.
Zhongjing Food announced that to thank shareholders for their long-term support and to help them better understand and experience the company’s products, the company has decided to give away Zhongjing American Ginseng for free. As of the market close on March 18, 2026, shareholders registered with 100 or more shares can claim one free package of Zhongjing American Ginseng (10g×10 bags).
Tiany Medical announced that its subsidiary, Ningbo Tianyi Pharmaceutical Technology Co., Ltd., recently received the “Drug Registration Certificate” issued by the National Medical Products Administration. The drug is Sodium Citrate Hemofiltration Replacement Solution, with main ingredients of sodium chloride and sodium citrate. It is an injectable, 5000ml in volume, classified as a Category 4 chemical drug, with the approval number GuoYaoZhunZi H20263506, valid until March 2, 2031. This product is used in continuous renal replacement therapy (CRRT) to achieve local anticoagulation and replenish replacement fluid. The core component, sodium citrate, binds with calcium ions in the blood to form soluble chelates, reducing free calcium ion concentration in the blood, thereby inhibiting coagulation and achieving local anticoagulation during extracorporeal circulation. This reduces the risk of filter clotting and is especially suitable for blood purification treatments for patients with high bleeding risk.